首页 > 市场调查报告书 > 製药

生物製剂分子标靶治疗学

市场调查报告书

商品编码

1563398

单株抗体市场规模、份额、成长分析，按来源类型、按生产类型、按应用、按最终用途、按地区 - 行业预测，2024-2031 年

Monoclonal Antibodies Market Size, Share, Growth Analysis, By Source Type, By Production Type, By Application, By End-use, By Region - Industry Forecast 2024-2031

出版日期: 2024年09月26日 | 出版商:

SkyQuest | 英文 211 Pages | 商品交期: 3-5个工作天内

价格

简介目录

2022年全球单株抗体市场规模估值为2,110亿美元，预测期间（2024-2031年）复合年增长率为11.5%，从2023年的2,352.7亿美元增至2031年的5,620.3亿美元，预估也会增长。

单株抗体 (mAb) 是透过克隆特定白血球从单一细胞株产生的抗体。由于其高特异性和功效，这些抗体被用于药物开发和作为各种疾病的治疗剂。全球慢性病盛行率的上升预计将在未来几年推动单株抗体市场的显着成长。此外，随着医学研发的大量投资以及生物技术的进步，对这些抗体的需求预计将进一步增加。分子生物学的进步预计也将为单株抗体市场做出积极贡献，促进其销售和应用。随着单株抗体在医疗保健、製药和生物技术领域的应用不断扩大，该领域的供应商和开发商正在出现新的机会。然而，该市场面临开发成本高、上市时间长和安全问题等挑战，可能会阻碍成长。随着市场的发展，这些因素将继续成为重要的考虑因素。

市场概况
北美洲
- 美国
- 加拿大
欧洲
- 德国
- 西班牙
- 法国
- 英国
- 义大利
- 其他欧洲国家地区
亚太地区
- 中国
- 印度
- 日本
- 韩国
- 其他亚太地区
拉丁美洲
- 巴西
- 其他拉丁美洲地区
中东和非洲 (MEA)
- 海湾合作委员会国家
- 南非
- 其他中东/非洲地区

竞争格局

前5名企业对比
主要企业市场定位（2023年）
主要市场参与者所采取的策略
近期市集活动
主要企业市场占有率（2023年）

主要企业简介

Novartis AG（Switzerland）
Pfizer Inc.（US）
GlaxoSmithKline plc（UK）
Amgen Inc.（US）
Merck & Co., Inc.（US）
Daiichi Sankyo Company, Limited（Japan）
Abbott Laboratories（US）
AstraZeneca plc（UK）
Eli Lilly and Company（US）
Johnson & Johnson Services, Inc.（US）
Bayer AG（Germany）
Bristol Myers Squibb（US）
F. Hoffmann-La Roche Ltd.（Switzerland）
Viatris Inc.（US）
Biogen Inc.（US）
Thermo Fisher Scientific, Inc.（US）
Novo Nordisk A/S（Denmark）
Sanofi SA（France）
Merck KGaA（Germany）
Genmab A/S（Denmark）
Regeneron Pharmaceuticals, Inc.（US）
Incyte Corporation（US）

简介目录

Product Code: SQMIG35H2248

Global Monoclonal Antibodies Market size was valued at USD 211 billion in 2022 and is poised to grow from USD 235.27 billion in 2023 to USD 562.03 billion by 2031, growing at a CAGR of 11.5% during the forecast period (2024-2031).

Monoclonal antibodies (mAbs) are antibodies generated from a single cell lineage by cloning a specific white blood cell. These antibodies are utilized in drug development and as treatments for a variety of diseases due to their high specificity and effectiveness. The increasing prevalence of chronic diseases globally is expected to drive significant growth in the monoclonal antibody market in the coming years. Additionally, substantial investments in medical research and development, along with advancements in biotechnology, are anticipated to further enhance the demand for these antibodies. The progress in molecular biology is also expected to contribute positively to the monoclonal antibody market, boosting their sales and application. As monoclonal antibodies find expanding uses across healthcare, pharmaceuticals, and biotechnology sectors, new opportunities are emerging for suppliers and developers in this field. However, the market faces challenges, including high development costs, extended time-to-market, and safety concerns, which may hinder its growth. These factors are likely to remain key considerations as the market evolves.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Monoclonal Antibodies market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Monoclonal Antibodies Market Segmental Analysis

Global Monoclonal Antibodies Market is segmented by Source type, Production Type, Application, End-use, and region. Based on Source type, the market is segmented into Murine, Chimeric, Humanized, and Human. Based on Production Type, the market is segmented into In Vivo, and In Vitro. Based on Application, the market is segmented into Oncology, Autoimmune Diseases, Infectious Diseases, Neurological Diseases, and Others. Based on End-use, the market is segmented into Hospitals, Specialty Centers, and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.

Drivers of the Global Monoclonal Antibodies Market

The increasing global prevalence of chronic diseases has heightened the need for innovative treatments and therapeutics, leading to greater investments in medical research and development. Monoclonal antibodies are central to this R&D, offering critical solutions for managing a variety of chronic conditions. As a result, the growing reliance on monoclonal antibodies in the development of new therapies is expected to drive further market expansion. This trend suggests that the market for monoclonal antibodies will continue to grow as research progresses and new applications are discovered.

Restraints in the Global Monoclonal Antibodies Market

The development of monoclonal antibodies involves intricate and time-consuming research techniques, contributing to high R&D costs. These substantial expenses are reflected in the final product prices, which can limit market growth. The elevated cost of developing monoclonal antibodies makes the end products expensive, posing a challenge to market expansion. Consequently, the high development costs are a significant factor impacting the overall growth of the monoclonal antibody market.

Market Trends of the Global Monoclonal Antibodies Market

The expiration of patents for monoclonal antibodies presents promising opportunities for the development of biosimilars and biobetters. Companies can focus their research and development efforts on creating biosimilars for well-established monoclonal antibodies whose patents are nearing expiration. By investing in the development of these biosimilars, companies have the potential to capitalize on the market for these products and achieve significant long-term profits. This strategic move can offer substantial financial benefits as the market for original monoclonal antibodies becomes more competitive.

Introduction

Objectives of the Study
Definitions
Market Scope

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Market Overview Outlook
Supply Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Technology Analysis
Ecosystem of the Market
Supply chain Analysis
Case study Analysis
PESTEL Analysis
Regulatory Analysis
Innovation Matrix
Top Investment Analysis
Key Success Factor
Degree of Competition

Monoclonal Antibodies Market by Source type

Market Overview
Murine
Chimeric
Humanized
Human

Monoclonal Antibodies Market by Production Type

Market Overview
In Vivo
In Vitro

Monoclonal Antibodies Market by Application

Market Overview
Oncology
Autoimmune Diseases
Infectious Diseases
Neurological Diseases
Others

Monoclonal Antibodies Market by End-use

Market Overview
Hospitals
Specialty Centers
Others

Monoclonal Antibodies Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2023
Strategies Adopted by Key Market Players
Recent Activities in the Market
Key Companies Market Share (%), 2023

Key Company Profiles

Novartis AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GlaxoSmithKline plc (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Amgen Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck & Co., Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Daiichi Sankyo Company, Limited (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Abbott Laboratories (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AstraZeneca plc (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eli Lilly and Company (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Johnson & Johnson Services, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bayer AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bristol Myers Squibb (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
F. Hoffmann-La Roche Ltd. (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Viatris Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Biogen Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Thermo Fisher Scientific, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novo Nordisk A/S (Denmark)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanofi S.A. (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck KGaA (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Genmab A/S (Denmark)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Regeneron Pharmaceuticals, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Incyte Corporation (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments